Bio-Rad Currently Expects FY23 Non-GAAP Currency-Neutral Revenue Growth Of 0.8% (Previous Estimate Of 4.5%)
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories, Inc. (BIO) has revised its FY23 non-GAAP currency-neutral revenue growth estimate from 4.5% to 0.8%.
August 04, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bio-Rad Laboratories has significantly lowered its FY23 revenue growth forecast, which could negatively impact investor sentiment and the company's stock price.
Bio-Rad Laboratories has significantly reduced its FY23 non-GAAP currency-neutral revenue growth estimate. This downward revision could negatively impact investor sentiment and lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100